Previous 10 | Next 10 |
Athenex (NASDAQ: ATNX ) has expanded its strategic partnership with Chinese drug company, Guangzhou Xiangxue Pharmaceutical Co., Ltd., to exclusively develop and commercialize Athenex’s Oral Paclitaxel (both the capsule and the tablet formulations), Oral Irinotecan, as well as Tirba...
The agreement covers China, Hong Kong and Macao (the “Territory”) and represents an expansion of the existing relationship between the two companies. Athenex will receive payments of up to $200 million which include an upfront, development, sales and other milestone paym...
Shares of Athenex (NASDAQ: ATNX) , a clinical-stage biopharmaceutical company, slid 21.2% in the first hour of trading on Friday. The stock recovered some of that loss as investors digested pivotal trial results that the company released this morning, but it was still down 17.2% as ...
Gainers: LMP Automotive (NASDAQ: LMPX ) +95% . More news on: LMP Automotive Holdings, Inc., Sarepta Therapeutics, Inc., Cohen & Company Inc., Stocks on the move, Read more ...
Results from a Phase 3 clinical trial comparing Athenex's ( ATNX -17.4% ) oral paclitaxel (and oral absorption technology encequidar) to the intravenous (IV) formulation in metastatic breast cancer patients showed superior response and survival but with a mixed safety profile. Th...
NEW YORK , Dec. 13, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential misconduct at Athenex, Inc. ("Athenex" or the "Company") (NASDAQ:ATNX). The investigation focuses on whether the Company's Board of Directors and/...
Aethlon Medical (NASDAQ: AEMD ) -45% on pricing stock offering. More news on: Aethlon Medical, Inc., Aquestive Therapeutics, Inc., Tonix Pharmaceuticals Holding Corp., Stocks on the move, Read more ...
First oral taxane to demonstrate superior response rate and overall survival compared to IV paclitaxel in a Phase III clinical trial Data to be presented today in an oral presentation at the 2019 San Antonio Breast Cancer Symposium (SABCS) BUFFALO, N.Y., Dec. 13, 2019 (GLOBE NEWSWI...
BUFFALO, N.Y., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the details for its upcoming...
Before we ring in 2020, December will be ripe for swings in biotech stock prices. 2019 started strong, waned, and then regained momentum amid a slew of successful clinical trial results, several acquisition announcements, and positive drug approval decisions that came often months ahead of the U...
News, Short Squeeze, Breakout and More Instantly...
Athenex Inc. Company Name:
ATNX Stock Symbol:
NASDAQ Market:
To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (...
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO PR Newswire SAN FRANCISCO , May 1, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and At...
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $1...